

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Respectfully submitted,

 Reg. # 32,004

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1

2200 Clarendon Boulevard, Suite 1400

Arlington, VA 22201

Direct Dial: 703-812-5311

Facsimile: 703-243-6410

Email: zelano@mwzb.com

AJZ:jmm


Filed: 10 MAY 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE


Claims 3-8, 10-12 and 15 have been amended as follows:

3. (Amended) Compounds of general formula I according to ~~claims claim 1 and 2~~, in which

- A stands for the group  $=NR^2$ ,  
 W stands for oxygen, sulfur or two hydrogen atoms,  
 Z stands for the group  $=NR^{10}$ ,  $=N$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$  or the group



or A, Z and  $R^1$  together form the group




m, n and o stand for 0-3,


q stands for 1-6,

$R_a$ ,  $R_b$ ,  $R_c$ ,  $R_d$ ,  $R_e$ ,  $R_f$ , independently of one another, stand for hydrogen or methyl or the group  $=NR^{10}$ ,

X  
Y  
R<sup>1</sup>

stands for the group =NR<sup>9</sup> or =N-,  
stands for the group -CH<sub>2</sub>-,  
stands for phenyl, pyridyl, p-chlorophenyl, p-methylphenyl, p-methoxyphenyl, 5-chloro-2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole, 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl, or for phenyl or pyridyl that is substituted in one or more places with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, hydroxy, halogen, trifluoromethyl, or for the group






whereby phenyl, or substituted phenyl or naphthyl is not right in the  $=NR^2$  group in the meaning of A,

$R^2$

stands for hydrogen or methyl,

$R^3$

stands for pyridyl, or phenyl, or 1,2,3,4-tetrahydronaphthyl that is substituted by hydroxy, halogen, methyl or methoxy, or for the group



R<sup>5</sup> and R<sup>6</sup>, independently of one another, stand for hydrogen, halogen, methyl, methoxy or trifluoromethyl,

R<sup>4</sup> and R<sup>7</sup>, independently of one another, stand for hydrogen,

R<sup>9</sup> stands for hydrogen,

R<sup>10</sup> stands for hydrogen or methyl,


as well as their isomers and salts.

4. (Amended) Compounds of general formula I according to claims ~~claim 1 to 3~~, in which


A stands for the group =NR<sup>2</sup>,

W stands for oxygen,

Z stands for the group =NR<sup>10</sup>, =N-, -N(R<sup>10</sup>)- (CH<sub>2</sub>)<sub>q</sub>- or the group



or A, Z and R<sup>1</sup> together form the group




m, n and o stand for 0-3,


q stands for 1-6,

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>, independently of one another, stand for hydrogen or methyl or the group =NR<sup>10</sup>,

X  
Y  
R<sup>1</sup>

stands for the group =NR<sup>9</sup> or =N-,  
stands for the group -CH<sub>2</sub>-,  
stands for phenyl, pyridyl, 5-chloro-  
2,3-dihydroindenyl, 2,3-dihydroindenyl,  
thienyl, 6-fluoro-1H-indol-3-yl,  
naphthyl, 1,2,3,4-tetrahydronaphthyl,  
benzo-1,2,5-oxadiazole or 6,7-dimethoxy-  
1,2,3,4-tetrahydro-2-naphthyl or for a  
phenyl or pyridyl that is substituted in  
one more places with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub>  
alkoxy, hydroxy, halogen, or  
trifluoromethyl, or for the group
















R<sup>2</sup>

R<sup>3</sup>

whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR<sup>2</sup> group in the meaning of A, stands for hydrogen or methyl, stands for pyridyl or for phenyl, pyridyl or 1,2,3,4-tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group

$R^5$  and  $R^6$ , independently of one another, stand for hydrogen, halogen, methyl, methoxy, or trifluoromethyl,  
 $R^4$  and  $R^7$ , independently of one another, stand for hydrogen and halogen,  
 $R^9$  stands for hydrogen,  
 $R^{10}$  stands for hydrogen or methyl,  
 as well as their isomers and salts.



independently of one another, stand for  
hydrogen, halogen, methyl, methoxy, or  
trifluoromethyl,

independently of one another, stand for  
hydrogen and halogen,

stands for hydrogen,


stands for hydrogen or methyl,

5. (Amended) Compounds of general formula I according to ~~claims claim 1 to 3~~, in which


stands for the group  $=NR^2$ ,

stands for sulfur,

stands for the group  $=NR^{10}$ ,  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$  or the group






























or A, Z and  $R^1$  together form the group




m, n and o stand for 0-3,  
 q stands for 1-6,  
 R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>, independently of one another, stand  
 for hydrogen or methyl or the group  
 =NR<sup>10</sup>,  
 X stands for the group =NR<sup>9</sup> or =N-,  
 Y stands for the group -CH<sub>2</sub>-,  
 R<sup>1</sup> stands for phenyl, pyridyl, 5-chloro-  
 2,3-dihydroindenyl, 2,3-dihydroindenyl,  
 thienyl, 6-fluoro-1H-indol-3-yl,  
 naphthyl, 1,2,3,4-tetrahydronaphthyl,  
 benzo-1,2,5-oxadiazole or 6,7-dimethoxy-  
 1,2,3,4-tetrahydro-2-naphthyl or for  
 phenyl or pyridyl that is substituted in  
 one or more places with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-  
 C<sub>4</sub> alkoxy, hydroxy, halogen, or  
 trifluoromethyl, or for the group

09831506 . 091401

09831506-091401




whereby phenyl, or substituted phenyl or naphthyl is not right in the  $=NR^2$  group in the meaning of A,

$R^2$

stands for hydrogen or methyl,

$R^3$

stands for pyridyl or for phenyl, pyridyl or 1,2,3,4-tetrahydronaphthyl that is substituted in one or more places with hydroxy, halogen, methyl or methoxy, or for the group



$R^5$  and  $R^6$ , independently of one another, stand for hydrogen, halogen, methyl, methoxy or trifluoromethyl,

$R^4$  and  $R^7$ , independently of one another, stand for hydrogen and halogen,

$R^9$  stands for hydrogen,

$R^{10}$  stands for hydrogen or methyl,


as well as their isomers and salts.

6. (Amended) Compounds of general formula I according to claims claim 1 to 3, in which


A stands for the group  $=NR^2$ ,

W stands for two hydrogen atoms,

Z stands for the group  $=NR^{10}$ ,  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$  or the group



or A, Z, and  $R^1$  together form the group



m, n and o

q

stand for 0-3,


stands for 1-6,

























$R_a, R_b, R_c, R_d, R_e, R_f$ , independently of one another, stand for hydrogen or methyl or the group  $=NR^{10}$ ,

X stands for the group  $=NR^9$  or  $=N-$ ,

Y stands for the group  $-CH_2-$ ,

$R^1$  stands for phenyl, pyridyl, 5-chloro-2,3-dihydroindenyl, 2,3-dihydroindenyl, thienyl, 6-fluoro-1H-indol-3-yl, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzo-1,2,5-oxadiazole or 6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl or for a phenyl or pyridyl that is substituted in one or more places with  $C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy, hydroxy, halogen, or trifluoromethyl, or for the group














		
		
		
		
		
		
		
		

whereby phenyl, or substituted phenyl or naphthyl is not right in the =NR<sup>2</sup> group in the meaning of A, stands for hydrogen or methyl,

R<sup>2</sup>

R<sup>3</sup>

stands for pyridyl or for phenyl,  
pyridyl or 1,2,3,4-tetrahydronaphthyl  
that is substituted in one or more  
places with hydroxy, halogen, methyl or  
methoxy, or for the group

R<sup>4</sup> and R<sup>7</sup>,

independently of one another, stand for  
hydrogen, halogen, methyl, methoxy or  
trifluoromethyl,

R<sup>5</sup> and R<sup>6</sup>,

independently of one another, stand for  
hydrogen and halogen,

R<sup>9</sup>

stands for hydrogen,

R<sup>10</sup>

stands for hydrogen or methyl,

as well as their isomers and salts.



7. (Amended) Use of the compounds of general formula I, according to ~~claims claim 1 to 6~~, for the production of a pharmaceutical agent for the treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis, injuries to the nerve tissue, and for inhibiting the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents.

8. (Amended) Pharmaceutical agent that contains at least one compound according to ~~claims claim 1 to 6~~.

10. (Amended) Compounds according to ~~claims 1 to claim 6~~ and pharmaceutical agents according to ~~claims claim 6 and 8~~ with suitable formulations and vehicles.

11. (Amended) Use of the compounds of formula I according to ~~claims claim 1 to 6~~ as inhibitors of tyrosine kinases KDR and FLT.

12. (Amended) Use of the compounds of general formula I according to ~~claims claim 1 to 6~~ in the form of a pharmaceutical preparation for enteral, parenteral and oral administration.

15. (Amended) Compounds of general formula V according to ~~claims claim 13 and 14~~ for the production of a pharmaceutical agent for the treatment of tumors, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome,

transplant rejections and glomerulopathy, fibrotic diseases, such as cirrhosis of the liver, mesangial-cell-proliferative diseases, arteriosclerosis, injuries to the nerve tissue, and for inhibiting the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents.

09831506-091401